Effect of melatonin on the fatigue, sleep, and depression symptom cluster in breast cancer according to dosage and treatment phase: A systematic review and meta-analysis
Abstract
e24112
Background:
Patients with breast cancer (BC) frequently experience a debilitating symptom cluster of sleep disturbances, depression, and fatigue, significantly impairing quality of life. While melatonin is a common supportive therapy, clinical trials yield conflicting results due to heterogeneous protocols. This meta-analysis clarifies melatonin’s efficacy by evaluating the pharmacological threshold (High-dose: ≥10mg vs. Low-dose: < 10mg) and clinical treatment phase (Active Treatment vs. Post-Treatment).
Methods:
Following PRISMA guidelines, a systematic search of PubMed, Embase, and Cochrane identified eight RCTs comparing oral melatonin to placebo in BC patients. Outcomes were sleep quality, depression, and fatigue, measured via Standardized Mean Difference (SMD). Data were pooled using random-effects models. Pre-specified subgroup analyses investigated dosage (≥10mg vs. < 10mg) and treatment phase (Active vs. Post-Treatment). Heterogeneity was assessed using the I
2
statistic and Cochrane Q test to ensure statistical rigor.
Results:
Eight RCTs involving 675 unique patients were included. For depression, a significant dose-dependent benefit was identified; high-dose melatonin (≥10mg) significantly reduced symptoms (SMD -1.07; 95% CI -1.43 to -0.71; P < 0.00001; I
2
= 0%), whereas low-dose ( < 10mg) had no significant effect (P = 0.83). For fatigue, a robust benefit was observed specifically during radiotherapy (SMD -1.33; 95% CI -1.82 to -0.84; P < 0.00001), while…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 675 participants or records.
Read the paper
Related studies
- Tryptophan Metabolism and Gut-Brain Homeostasis
- Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer’s Disease and MCI: A Review
- Prioritized Research for the Prevention, Treatment, and Reversal of Chronic Disease: Recommendations From the Lifestyle Medicine Research Summit
- Relationship between sleep disorders and gut dysbiosis: what affects what?
- The role of CLOCK gene in psychiatric disorders: Evidence from human and animal research
- Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer’s Disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.